

# EPIAXIS THERAPEUTICS

**A NOVEL EPIGENETICALLY DIRECTED IMMUNO  
ONCOLOGICAL APPROACH TO PROLONG CANCER  
REMISSION**

**J S Crisp CEO**

October 2018

[www.epiaxistherapeutics.com](http://www.epiaxistherapeutics.com)

## Overview

- Epigenetically directed IO Co
- Primary target is LSD1
- Initial disease indication is MBC
- Novel discovery assets
- Open clinical program
- Strategy is to prolong remission via our novel IO axis
- Positioning to become the leading LSD1 Co

## Highlights

### 1. Novel FIC inhibitors that block nuclear entry of LSD1p

- Independent & superior to catalytic inhibitors
- Highly specific to the NLS region

### 2. Novel IO axis

- Reprogram the CTC/CSC epigenome
- Reeducate the immune response

### 3. Open Phase 1b in MBC

## Novel Assets

- Family of linear & cyclic peptides
- Evaluated in numerous in vitro, in vivo & ex vivo models
- Benchmarked against clinical LS assets
- Undergoing further characterisation
- Preclinical selection pending
- Highly valuable

## Hypothesis

- That lowering nuclear LSD1 in combination with chemotherapy in an MBC setting provides:
  - Reversal of the mesenchymal to epithelial transition
  - Elicitation of an innate & adaptive immune response
  - Removal of checkpoint blockage
  - Clearance of the CTC/CSC burden to prolong remission

## Phase 1B

- **EpiPRIME<sup>®</sup> for Prolonging Remission in Metastatic Disease**
- **PoC cohort dose escalation of Phelzine Sulfate with Abraxane<sup>®</sup> in MBC**
- **3 centers: Canberra, Wollongong & Sydney**
- **4 patients completed**
- **Interim clinical readout in Q219**

## Key Phase 1 Features

1. First as an epigenetic combination with SoC Abraxane in MBC
2. Monitoring CTC/CSC burden by enumeration & quantification of their stem & mesenchymal phenotypes, both at a protein & transcriptome level
3. Enumeration of T cell activity & cytokine profiles
4. Quantification of epigenomic reprogramming

## IP

- Five patent families
- Both MoU & CoMpatents
- AU, CA, CH, EU, IN, JP, SG & U
- 3 granted patents thus far
- All exclusively licensed from C
- New IP pending



## What's Next?

1. Complete **Phase 1b**
2. Nominate our **leadMBC** candidate
3. Compile our **data-room**
4. Invite **interest from Pharma** beginning early 2019
5. Open to **Capital raising** thereafter

## Summary

- Clinically staged **10** company
- **Novel, best in class** assets
- **Reprogramming** of the **CTC/CSC** epigenome
- **Prolong remission** & ultimately prevent metastatic disease
- Extensive in vitro, in vivo & ex vivo **dataset**
- A great **team**, strong **IP**
- Reaching critical inflexion point to become the **leading LSD1 Co**

**Thank you**

**Dr J S Crisp, CEO**

[j.chrisp@epiaxistherapeutics.com](mailto:j.chrisp@epiaxistherapeutics.com)

**+61 421 012 268**

**[www.epiaxistherapeutics.com](http://www.epiaxistherapeutics.com)**